Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.

Biotechnology

Education

Parthenon Therapeutics

Parthenon Therapeutics' headquarters in Cambridge, MA, United States

Laurent Audoly

C. Glenn Begley

John Goldberg

Irena Lerentracht Webster

Thomas Schürpf

Joseph Paul Eder

Melissa Lambeth Kemp

Marina Kochetkova

Rong Li

Ezogelin Oflazoglu-Gruyters

Paolo Provenzano

Michael Cecchini

Ellen Puré

Wolf Hervé Fridman

Mace Rothenberg

Antoine Italiano

Pamela Munster

The Scientific Team at Parthenon Therapeutics focuses on researching and developing innovative anti-cancer therapies that target and reprogram the tumor microenvironment (TME). They conduct rigorous studies to understand the interplay between cancer cells and the TME, design and test novel drug candidates like PRTH-101, and aim to identify the most effective treatments for different patient populations. Their work is pivotal in overcoming the barriers that shield tumors from the immune system, ultimately advancing the efficacy of cancer therapies.

Scientific Team

The Leadership Team at Parthenon Therapeutics is responsible for driving the strategic direction of the company in developing innovative anti-cancer therapies. Comprising experts in clinical sciences, translational medicine, research, and operational strategy, the team collaborates to oversee drug development initiatives, ensure alignment with scientific goals, and optimize the progression of therapeutic candidates like PRTH-101 towards clinical implementation, ultimately enhancing patient outcomes.

Leadership Team

The Clinical and Medical Team at Parthenon Therapeutics leads the strategic planning and execution of clinical trials, oversees patient safety and regulatory compliance, and integrates translational medicine and bioinformatics insights to guide the development of innovative anti-cancer therapies. They collaborate cross-functionally to ensure that drug candidates are effectively brought from research stages to clinical application, ultimately aiming to provide targeted treatments to patients with challenging cancer types.

Clinical and Medical Team

The Data Science and Bioinformatics team at Parthenon Therapeutics leverages advanced computational techniques and biological data analysis to decode the complexities of the tumor microenvironment. By integrating large-scale data sets and developing predictive models, the team identifies novel therapeutic targets and optimizes drug candidate selection. Their insights drive the design and personalization of anti-cancer therapies, ensuring treatments are effective for the right patients at the right time.

Data Science and Bioinformatics

Parthenon Therapeutics

Org chart

Board & advisors

Teams

Scientific Team

Leadership Team

Clinical and Medical Team

Data Science and Bioinformatics

Offices

Parthenon Therapeutics

Org chart

Board & advisors

Teams

Scientific Team

Leadership Team

Clinical and Medical Team

Data Science and Bioinformatics

Offices

Related companies